Thus, we posited that the apparent proclivity of bone-disseminated ER+ (vs. ER−) breast cancer cells to form clinically-evident osteolytic BMET could be attributable, at least in part, to pro-osteolytic effects of tumoral ERα signaling. This evidence concerns the gene ESR1 and breast cancer.